{"id":"W4205422786","doi":"10.1016/j.ygyno.2021.12.025","title":"Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck; AstraZeneca","keywords":"Medicine; Olaparib; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Ovarian cancer; BRCA mutation; Tolerability; Progression-free survival; Discontinuation; Progressive disease; Population; Nausea; Chemotherapy; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001799713,0.0005439039,0.001432302,0.000251511,0.0001681554,0.0008241255,0.0005133927,0.0004851117,0.002952009],"category_scores_gemma":[0.00163468,0.0002724231,0.001525324,0.0003817482,0.0002378148,0.0005427004,0.0002917206,0.0007319148,0.0004517555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006568556,"about_ca_system_score_gemma":0.0007452087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004467736,"about_ca_topic_score_gemma":0.001133702,"domain_scores_codex":[0.9991428,0.0003723799,0.00006353983,0.0002025323,0.0001388493,0.00007992821],"domain_scores_gemma":[0.9987578,0.0004042847,0.000392593,0.00009099222,0.0001413199,0.0002129679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6665325,0.005194582,0.1948044,0.002447447,0.01281695,0.0004876639,0.0001656721,0.002263046,0.01591608,0.0002291189,0.003931656,0.0952109],"study_design_scores_gemma":[0.2804072,0.2046741,0.4699152,0.0003499585,0.01679125,0.002368664,0.0001719166,0.006770864,0.006103504,0.000492715,0.01184468,0.000110008],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894602,0.004741296,0.0004463957,0.0001887581,0.00002735568,0.0006564586,0.002855419,0.00002597805,0.00159819],"genre_scores_gemma":[0.9940438,0.0009322386,0.0004722608,0.0002957848,0.00009927768,0.0003277328,0.003322441,0.000008980259,0.0004974552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002952009,"threshold_uncertainty_score":0.009875476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02167457305031685,"score_gpt":0.326532917806484,"score_spread":0.3048583447561672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}